Abstract
Atezolizumab plus bevacizumab (atezo+bev) is standard of care first-line treatment in eligible patients with advanced HCC, but clear guidance on follow-up treatment is lacking. In IMbrave150, 36% of patients received systemic treatment after atezo+bev. Real-world evidence is needed to describe treatment patterns in clinical practice. This study describes the real-world use of atezo+bev and subsequent systemic treatments in patients with HCC in the United States (US).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
